metformin has been researched along with Triple Negative Breast Neoplasms in 31 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Microscopic imaging, the formation of 3D multicellular tumour spheroids, immunocytochemistry, flow cytometry, Annexin V Assay, Caspase 3/7 Apoptosis Assay, tube formation assay and analysis, and WST-1 cell viability assay evaluated the formation of MCTS, morphologic changes, cell viability, apoptosis activity and the expression levels of ALDH1A1, CD44 and CD24 on the cell surface, MDA-MB231 triple-negative breast cancer, tamoxifen (Tmx) resistant variant (MDA-MB-231-TmxR)." | 7.96 | A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. ( Burov, SV; Haq, S; Harless, W; Markvicheva, E; Qorri, B; Sambi, M; Samuel, V; Szewczuk, MR, 2020) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 7.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| "Microscopic imaging, the formation of 3D multicellular tumour spheroids, immunocytochemistry, flow cytometry, Annexin V Assay, Caspase 3/7 Apoptosis Assay, tube formation assay and analysis, and WST-1 cell viability assay evaluated the formation of MCTS, morphologic changes, cell viability, apoptosis activity and the expression levels of ALDH1A1, CD44 and CD24 on the cell surface, MDA-MB231 triple-negative breast cancer, tamoxifen (Tmx) resistant variant (MDA-MB-231-TmxR)." | 3.96 | A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. ( Burov, SV; Haq, S; Harless, W; Markvicheva, E; Qorri, B; Sambi, M; Samuel, V; Szewczuk, MR, 2020) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 3.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| "Metformin treatment in glucose-starved and 2DG (10 mM) exposed TNBC cells inhibited the mTOR pathway compared to non-treated glucose-starved cells or 2DG/metformin alone treated controls." | 1.91 | Metabolic heterogeneity in TNBCs: A potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy. ( Büsselberg, D; Samuel, SM; Satheesh, NJ; Triggle, CR; Varghese, E, 2023) |
| "Metformin treated cells had higher fatty and amino acid levels with lower purine nucleotide levels, which is relevant for understanding the anticancer mechanisms of metformin." | 1.62 | Metabolic profiling of attached and detached metformin and 2-deoxy-D-glucose treated breast cancer cells reveals adaptive changes in metabolome of detached cells. ( Bizjak, M; Gole, B; Magnes, C; Pavlin, M; Potočnik, U; Repas, J; Zügner, E, 2021) |
| "Metformin has been shown to have antitumor effects by lowering serum levels of the mitogen insulin and having pleiotropic effects on cancer cell signaling pathways." | 1.62 | Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer. ( Camacho, L; Chen, F; Huang, S; Jiralerspong, S; Kothapalli, S; Li, Y; Ma, F; Mo, Q; Wei, G; Xue, L; Yue, F, 2021) |
| "Hylaluronic acid engrafted metformin loaded graphene oxide (HA-GO-Met) nanoparticles exhibited an anti-cancer efficacy at much lower dosage as compared to metformin alone." | 1.62 | Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer. ( Adhikary, A; Basu, A; Bose, A; Chattopadhyay, D; Chattopadhyay, S; Ghosh, A; Gupta, P; Upadhyay, P, 2021) |
| "As metformin is a glucose lowering drug, we hypothesized that normoglycemia will sensitize MDA-MB-231 cells to the anti-proliferative effect of metformin." | 1.40 | The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. ( Bark, D; Dyck, JR; Soltys, CL; Sung, MM; Zordoky, BN, 2014) |
| "Metformin has been shown to selectively kill cancer stem cells, and triple-negative breast cancer (TNBC) cell lines are more sensitive to the effects of metformin as compared to luminal breast cancer." | 1.40 | Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. ( Anderson, SM; Cochrane, DR; Edgerton, SM; Howe, EN; Richer, JK; Spoelstra, NS; Thor, AD; Wahdan-Alaswad, RS, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (58.06) | 24.3611 |
| 2020's | 13 (41.94) | 2.80 |
| Authors | Studies |
|---|---|
| Repas, J | 1 |
| Zügner, E | 1 |
| Gole, B | 1 |
| Bizjak, M | 2 |
| Potočnik, U | 1 |
| Magnes, C | 1 |
| Pavlin, M | 2 |
| Sahu, P | 1 |
| Camarillo, IG | 1 |
| Sundararajan, R | 1 |
| Cheng, T | 1 |
| Wang, C | 1 |
| Lu, Q | 1 |
| Cao, Y | 1 |
| Yu, W | 1 |
| Li, W | 1 |
| Liu, B | 2 |
| Gao, X | 1 |
| Lü, J | 1 |
| Pan, X | 1 |
| Samuel, SM | 2 |
| Varghese, E | 2 |
| Satheesh, NJ | 1 |
| Triggle, CR | 1 |
| Büsselberg, D | 2 |
| Song, J | 1 |
| Du, J | 1 |
| Han, L | 1 |
| Lin, X | 1 |
| Fan, C | 1 |
| Chen, G | 1 |
| Fenn, K | 1 |
| Maurer, M | 1 |
| Lee, SM | 1 |
| Crew, KD | 1 |
| Trivedi, MS | 1 |
| Accordino, MK | 1 |
| Hershman, DL | 1 |
| Kalinsky, K | 1 |
| Lee, JO | 1 |
| Kang, MJ | 1 |
| Byun, WS | 1 |
| Kim, SA | 1 |
| Seo, IH | 1 |
| Han, JA | 1 |
| Moon, JW | 1 |
| Kim, JH | 1 |
| Kim, SJ | 1 |
| Lee, EJ | 1 |
| In Park, S | 1 |
| Park, SH | 1 |
| Kim, HS | 1 |
| Sambi, M | 1 |
| Samuel, V | 1 |
| Qorri, B | 1 |
| Haq, S | 1 |
| Burov, SV | 1 |
| Markvicheva, E | 1 |
| Harless, W | 1 |
| Szewczuk, MR | 1 |
| Sulaiman, A | 1 |
| McGarry, S | 1 |
| Chambers, J | 1 |
| Al-Kadi, E | 1 |
| Phan, A | 1 |
| Li, L | 1 |
| Mediratta, K | 1 |
| Dimitroulakos, J | 1 |
| Addison, C | 1 |
| Li, X | 1 |
| Wang, L | 2 |
| Xue, L | 1 |
| Chen, F | 1 |
| Yue, F | 1 |
| Camacho, L | 1 |
| Kothapalli, S | 1 |
| Wei, G | 1 |
| Huang, S | 1 |
| Mo, Q | 1 |
| Ma, F | 1 |
| Li, Y | 1 |
| Jiralerspong, S | 1 |
| Pateliya, B | 1 |
| Burade, V | 1 |
| Goswami, S | 1 |
| Basu, A | 1 |
| Upadhyay, P | 1 |
| Ghosh, A | 1 |
| Bose, A | 1 |
| Gupta, P | 1 |
| Chattopadhyay, S | 1 |
| Chattopadhyay, D | 1 |
| Adhikary, A | 1 |
| Babak, MV | 1 |
| Chong, KR | 1 |
| Rapta, P | 1 |
| Zannikou, M | 1 |
| Tang, HM | 1 |
| Reichert, L | 1 |
| Chang, MR | 1 |
| Kushnarev, V | 1 |
| Heffeter, P | 1 |
| Meier-Menches, SM | 1 |
| Lim, ZC | 1 |
| Yap, JY | 1 |
| Casini, A | 1 |
| Balyasnikova, IV | 1 |
| Ang, WH | 1 |
| Anselmino, LE | 1 |
| Baglioni, MV | 1 |
| Malizia, F | 1 |
| Laluce, NC | 1 |
| Etichetti, CB | 1 |
| Marignac, VLM | 1 |
| Rozados, V | 1 |
| Scharovsky, OG | 1 |
| Girardini, J | 1 |
| Rico, MJ | 1 |
| Menacho Márquez, M | 1 |
| Strekalova, E | 1 |
| Malin, D | 1 |
| Rajanala, H | 1 |
| Cryns, VL | 1 |
| Wokoun, U | 1 |
| Hellriegel, M | 1 |
| Emons, G | 1 |
| Gründker, C | 1 |
| Amaral, I | 1 |
| Silva, C | 1 |
| Correia-Branco, A | 1 |
| Martel, F | 1 |
| Athreya, AP | 1 |
| Gaglio, AJ | 1 |
| Cairns, J | 1 |
| Kalari, KR | 1 |
| Weinshilboum, RM | 1 |
| Kalbarczyk, ZT | 1 |
| Iyer, RK | 1 |
| Varghese, S | 1 |
| Kubatka, P | 1 |
| Banerjee, A | 1 |
| Birts, CN | 1 |
| Darley, M | 1 |
| Parker, R | 1 |
| Mirnezami, AH | 1 |
| West, J | 1 |
| Cutress, RI | 1 |
| Beers, SA | 1 |
| Rose-Zerilli, MJJ | 1 |
| Blaydes, JP | 1 |
| Lee, J | 1 |
| Yesilkanal, AE | 1 |
| Wynne, JP | 1 |
| Frankenberger, C | 1 |
| Liu, J | 1 |
| Yan, J | 1 |
| Elbaz, M | 1 |
| Rabe, DC | 1 |
| Rustandy, FD | 1 |
| Tiwari, P | 1 |
| Grossman, EA | 1 |
| Hart, PC | 1 |
| Kang, C | 1 |
| Sanderson, SM | 1 |
| Andrade, J | 1 |
| Nomura, DK | 1 |
| Bonini, MG | 1 |
| Locasale, JW | 1 |
| Rosner, MR | 1 |
| Malavašič, P | 1 |
| Pirkmajer, S | 1 |
| Koh, M | 1 |
| Lee, JC | 1 |
| Min, C | 1 |
| Moon, A | 1 |
| Marini, C | 1 |
| Salani, B | 1 |
| Massollo, M | 1 |
| Amaro, A | 1 |
| Esposito, AI | 1 |
| Orengo, AM | 1 |
| Capitanio, S | 1 |
| Emionite, L | 1 |
| Riondato, M | 1 |
| Bottoni, G | 1 |
| Massara, C | 1 |
| Boccardo, S | 1 |
| Fabbi, M | 1 |
| Campi, C | 1 |
| Ravera, S | 1 |
| Angelini, G | 1 |
| Morbelli, S | 1 |
| Cilli, M | 1 |
| Cordera, R | 1 |
| Truini, M | 1 |
| Maggi, D | 1 |
| Pfeffer, U | 1 |
| Sambuceti, G | 1 |
| Zordoky, BN | 1 |
| Bark, D | 1 |
| Soltys, CL | 1 |
| Sung, MM | 1 |
| Dyck, JR | 1 |
| Besic, N | 1 |
| Satej, N | 1 |
| Ratosa, I | 1 |
| Horvat, AG | 1 |
| Marinko, T | 1 |
| Gazic, B | 1 |
| Petric, R | 1 |
| Wellberg, EA | 1 |
| Anderson, SM | 2 |
| Wahdan-Alaswad, RS | 1 |
| Cochrane, DR | 1 |
| Spoelstra, NS | 1 |
| Howe, EN | 1 |
| Edgerton, SM | 2 |
| Thor, AD | 2 |
| Richer, JK | 1 |
| Marinello, PC | 1 |
| da Silva, TN | 1 |
| Panis, C | 1 |
| Neves, AF | 1 |
| Machado, KL | 1 |
| Borges, FH | 1 |
| Guarnier, FA | 1 |
| Bernardes, SS | 1 |
| de-Freitas-Junior, JC | 1 |
| Morgado-Díaz, JA | 1 |
| Luiz, RC | 1 |
| Cecchini, R | 1 |
| Cecchini, AL | 1 |
| Talarico, G | 1 |
| Orecchioni, S | 1 |
| Dallaglio, K | 1 |
| Reggiani, F | 1 |
| Mancuso, P | 1 |
| Calleri, A | 1 |
| Gregato, G | 1 |
| Labanca, V | 1 |
| Rossi, T | 1 |
| Noonan, DM | 1 |
| Albini, A | 1 |
| Bertolini, F | 1 |
| Wahdan-Alaswad, R | 1 |
| Harrell, JC | 1 |
| Fan, Z | 1 |
1 trial available for metformin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Dose-Response Relationship, Dru | 2020 |
30 other studies available for metformin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Metabolic profiling of attached and detached metformin and 2-deoxy-D-glucose treated breast cancer cells reveals adaptive changes in metabolome of detached cells.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Female; Humans; Hypoglycemic Agents; Metabolome; | 2021 |
Enhanced Antiproliferation Potency of Electrical Pulse-Mediated Metformin and Cisplatin Combination Therapy on MDA-MB-231 Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Ele | 2022 |
Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Metformin; Resveratrol; Triple Negative Bre | 2022 |
Metabolic heterogeneity in TNBCs: A potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Female; Glucose; Humans; Metformin; TOR Serine-T | 2023 |
The Effect of Metformin on Triple-Negative Breast Cancer Cells and Nude Mice.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Humans; Metalloproteases; Metformin; Mice; Mice, Nude | 2023 |
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2019 |
A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Apoptosis; Aspirin; Breast Neoplasms; CD24 A | 2020 |
Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Fe | 2020 |
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Insulins; Metformin; Receptor, IGF Typ | 2021 |
Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cell Line, Tumor; Cell Prolifer | 2021 |
Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; C | 2021 |
Interfering with Metabolic Profile of Triple-Negative Breast Cancers Using Rationally Designed Metformin Prodrugs.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Coordination Complexes; Drug Evaluation | 2021 |
Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.
Topics: Animals; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemother | 2021 |
Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases | 2017 |
Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cel | 2017 |
Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Female; Gl | 2018 |
Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Female; Gene Expression Profiling; Gene E | 2018 |
High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell L | 2019 |
Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization.
Topics: Alcohol Oxidoreductases; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA-Binding P | 2019 |
Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Citric Acid Cycle; Electron Transport; Female; | 2019 |
Comparison of the effects of metformin on MDA-MB-231 breast cancer cells in a monolayer culture and in tumor spheroids as a function of nutrient concentrations.
Topics: AMP-Activated Protein Kinases; Cell Culture Techniques; Cell Survival; Enzyme Activation; Female; Gl | 2019 |
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Ani | 2013 |
Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Glucose; Heterografts; Hexokinase; Metformin; Mice | 2013 |
The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Line, Tumor; Glucose; Humans; Insulin; MA | 2014 |
Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients - a retrospective study of clinical and tumor characteristics.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus; Female; Humans; Metformin; Middle Aged; Prognosis | 2014 |
FASNating targets of metformin in breast cancer stem-like cells.
Topics: Fatty Acid Synthase, Type I; Female; Humans; Metformin; MicroRNAs; Neoplastic Stem Cells; Triple Neg | 2014 |
Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b.
Topics: 3' Untranslated Regions; Apoptosis; Cell Line, Tumor; Fatty Acid Synthase, Type I; Female; Gene Expr | 2014 |
Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor β1 induction.
Topics: Apoptosis; Cell Proliferation; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Humans; M | 2016 |
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Topics: Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Asp | 2016 |
Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Topics: Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Claudins; Disease-Free Surv | 2016 |